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The study of the regulatory networks that con-
trol cell fate decisions and developmental pro-
cesses in mammals has mainly been focused 
on identifying the molecular components and 
their interactions, usually in a qualitative rather 
than a quantitative manner. A successful exam-
ple of this approach is the well-characterized 
system of terminal differentiation of B cells, 
which allows study of the interconnected pro-
cesses of cellular expansion, differentiation, and 
cell fate determination. Antigen-activated B cells 
receive additional signals from helper T cells be-
fore undergoing proliferative expansion. After 
a few rounds of division, some of the resulting 
B-blasts migrate to the extrafollicular regions in 
the spleen or to the medullary cords of lymph 
nodes, where they continue to proliferate be-
fore differentiating into antibody-secreting cells 
(ASCs; the term is used here to include cycling 
plasmablasts and plasma cells). This leads to the 
immediate production of neutralizing antibody 
that can be critical to the control of the spread 
of an infection as well as to the formation of 
immune complexes that assist antigen presenta-
tion (MacLennan et al., 2003; Belver et al., 2011). 
Such extrafollicular responses can involve anti-
body (Ab) class switch recombination (CSR) to 
various isotypes, allowing the Abs produced to 
acquire a wide range of effector functions and 
to disseminate toward infected tissues. Other 
B-blasts migrate to the B cell follicles, make 
cognate interactions with antigen-primed T cells 
and form germinal centers (GC). After accumu-
lation of somatic mutations in their immuno-
globulin genes, GC-B cells are subjected to 
antigen affinity-based selection. This process 
shapes the BCR repertoire of antigen experi-
enced B cells by providing survival signals to non 
self-reactive, high affinity clones to become long-
lived plasma cells or memory B cells (Ho et al., 
1986; Jacob et al., 1991a; Liu et al., 1991).
B cell terminal differentiation is a particularly 
attractive system in which to study gene regula-
tory networks because of the well-defined gene 
expression changes that occur during the pro-
gression from naive B cells to ASCs and the 
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A single microRNA (miRNA) can regulate the expression of many genes, though the level of 
repression imparted on any given target is generally low. How then is the selective pressure 
for a single miRNA/target interaction maintained across long evolutionary distances? We 
addressed this problem by disrupting in vivo the interaction between miR-155 and PU.1 in 
mice. Remarkably, this interaction proved to be key to promoting optimal T cell–dependent 
B cell responses, a previously unrecognized role for PU.1. Mechanistically, miR-155 inhibits 
PU.1 expression, leading to Pax5 down-regulation and the initiation of the plasma cell 
differentiation pathway. Additional PU.1 targets include a network of genes whose prod-
ucts are involved in adhesion, with direct links to B–T cell interactions. We conclude that 
the evolutionary adaptive selection of the miR-155–PU.1 interaction is exercised through 
the effectiveness of terminal B cell differentiation.
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a negative regulator of CSR (Vigorito et al., 2007). Third, 
PU.1 expression in B cells is elevated in the absence of miR-155, 
a miRNA that regulates T cell–dependent antibody responses 
in a B cell intrinsic manner (Vigorito et al., 2007). Last, the 
role of PU.1 in terminal B cell differentiation is only begin-
ning to be understood (Carotta et al., 2010b), so our investi-
gation might yield valuable new insights into the mechanisms 
of this process.
By removing the miR-155–binding site in the 3untrans-
lated region (UTR) of PU.1 in mice, we uncoupled PU.1 
expression from miR-155. This resulted in increased PU.1 
levels in B cells. Remarkably, a twofold change in expression 
of PU.1 led to an impaired extrafollicular response to immu-
nization in vivo and impaired CSR and plasma cell forma-
tion in cultured B cells. Mechanistically, we established that 
miR-155 is required for the initiation of the plasma cell dif-
ferentiation program because it down-regulates PU.1, which 
in turn down-regulates Pax5. Furthermore, we uncovered a 
network of genes regulated by PU.1 with functions in cellular 
adhesion, suggesting that PU.1 controls B–T cell interactions. 
Our results also highlighted the fact that small changes in the 
expression of particular genes can have profound effects in 
regulatory networks and that tight control of their abundance 
by miRNAs is essential for optimal function.
RESULTS
Increased expression of PU.1 in activated B cells  
upon disruption of miR-155 regulation
To reveal the effect of altered PU.1 expression due to the re-
moval of its regulation by miR-155, the highly conserved 
miR-155 recognition element in the 3UTR of Sfpi1, which 
encodes PU.1, was mutated in mice (Fig. 1 A). The mutation 
disrupts the “seed-match,” binding to miR-155 such that the 
repression by miR-155 is abolished (Fig. 1 B) without creating 
de novo seed-matches for any known miRNA reported in 
miRBase (Release 13.0, Sanger Institute). Mice were bred to 
produce homozygotes for the knock-in allele, which we termed 
PU.1155. PU.1155/155 mice were born at normal frequen-
cies within litters. As in miR-155/ mice (Rodriguez et al., 
2007), the proportions and numbers of developing and ma-
ture PU.1155/155 lymphoid subsets and myeloid cells showed 
no differences relative to WT (Table 1). These results are con-
sistent with the low expression of miR-155 in unstimulated 
cells (Thai et al., 2007; O’Connell et al., 2007).
To examine whether mutation of the miR-155–binding 
site in PU.1 altered its mRNA and protein expression, B cells 
were stimulated with LPS for 96 h in vitro, to induce expression 
of miR-155, before PU.1 expression was measured. Expres-
sion of PU.1 mRNA and protein was increased in both 
miR-155/ and PU.1155/155 B cells relative to WT controls 
(Fig. 1, C and D). The effect of miR-155 on PU.1 is specific 
to activated B cells, as the expression of PU.1 is equivalent in 
WT, PU.1155/155, and miR-155/ naive B cells (Fig. 4 B, 
PU.1) in developing B cells and in myeloid cells (Fig. 1 E). 
Moreover, the effect was restricted to PU.1 as another miR-155 
target, AID (encoded by Aicda), was expressed at WT levels in 
documented interactions between the major transcription 
factors involved. In qualitative terms, the changes in gene ex-
pression required for this process are regulated by the coordi-
nated activity of transcription factors that either maintain the 
B cell program (Pax5, Bach2, and Bcl6) or promote differen-
tiation (Blimp1 or IRF4; Martins and Calame, 2008). Inter-
estingly, the abundance of these transcription factors is tightly 
regulated in specific windows along the pathway of terminal 
B cell differentiation. For instance, haploinsufficient Bcl6 
B cells are less able to establish GC compared with their WT 
counterparts (Linterman et al., 2009). Thresholds of IRF4 
direct different outcomes of B cell differentiation: whereas 
low expression of IRF4 promotes GC development and CSR 
and blocks the formation of ASCs, the opposite occurs when 
it is highly expressed (Sciammas et al., 2006; Ochiai et al., 
2013). Thus, changes in the abundance of at least some com-
ponents of the network may affect the outcome of the differ-
entiation program. However, how thresholds and abundances 
are regulated in vivo is an issue that remains to be elucidated. 
This unresolved issue is of wide biological significance which 
has long been acknowledged in the context of many human 
developmental syndromes caused by partial, heterozygous 
chromosomal loss (Fisher and Scambler, 1994) and involving 
the deletion of critical haploinsufficient genes. Although those 
changes in gene expression can be limited in range (>1–2 
fold), they dramatically impact developmental processes lead-
ing to cancer susceptibility and tumor formation (Berger and 
Pandolfi, 2011).
A major mechanism to enable stringent control of gene 
expression involves microRNAs (miRNAs), with most genes in 
the genome being predicted to be under their control (Friedman 
et al., 2009). However, the effect of a particular miRNA on a 
specific gene is generally limited to no more than a two- to 
threefold change in expression. An unsolved question in the 
miRNA field is what keeps miRNA-responding elements 
under strict evolutionary purifying selection, if they merely 
fine-tune the expression of their targets. We speculate that the 
small changes imparted by miRNA regulation, at the very least 
in certain network components, may make a substantial contri-
bution to the efficiency of a particular biological process.
To shed some light on this problem, we assessed the im-
pact on terminal B cell differentiation in vivo of disrupting 
a miRNA-responding element within the mRNA of a par-
ticular transcription factor. This approach, which directly pre-
vents miRNA–target interactions, has rarely been used to 
investigate miRNA–target function (Dorsett et al., 2008), de-
spite being the only way to establish causative relations. We 
chose the transcription factor PU.1 for several reasons. First, it is 
already established as a dose-sensitive gene. PU.1 functions in 
a concentration-dependent manner to regulate gene expres-
sion in many cell lineages (Laslo et al., 2006; Carotta et al., 
2010a), and several animal models expressing variable amounts 
of PU.1 have altered hematopoiesis (Rosenbauer et al., 2004; 
Dakic et al., 2005; Iwasaki et al., 2005; Houston et al., 2007). 
Second, when overexpressed by means of retroviral transduc-
tion of mitogen- and cytokine-activated B lymphocytes, it is 
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significance of this interaction in vivo. We took advantage of 
our previous observations with miR-155/ mice in which we 
demonstrated a B cell–intrinsic defect in the T cell–dependent 
response to NP-KLH (Vigorito et al., 2007). We started by 
measuring the level of steady-state serum immunoglobulins 
IgM and IgG in the blood of PU.1155/155 mice. We ob-
served a significant reduction of serum IgM and IgG1 in 
PU.1155/155 relative to WT mice (Fig. 2 A). A similar, though 
greater, effect was observed in miR-155–deficient mice. As 
PU.1155–/155– B cells but up-regulated in miR-155/ (Fig. 1 C). 
These data demonstrate that the binding site of miR-155 in 
the PU.1 3UTR is functional and that miR-155 directly 
regulates the expression of PU.1 in activated B cells.
Impaired terminal B cell differentiation  
due to altered levels of PU.1 in vivo
Having established that miR-155 regulates the expression 
of PU.1 in activated B cells, we next studied the biological 
Figure 1. PU.1 expression is increased in activated B cells upon removal of the miR-155–binding site in its 3UTR. (A) Schematic representa-
tion of a portion of the 3UTR of the Sfpi1 locus showing the conserved 8-nt seed complementary to miR-155 (boxed) and the base changes introduced 
to disrupt miR-155 binding (red letters). (B) A luciferase reporter assay was used to validate PU.1 as a direct target of miR-155 and to assess whether  
the mutation introduced in the 3UTR of PU.1 disrupts miR-155 inhibition. WT (open bars) or mutant (filled [red] bars) plasmids containing the 3UTR  
genomic region of PU.1 were amplified and co-transfected in triplicates with no mimic, control mimic (miR-124a), and miR-155 mimic into HeLa cells. 
The data presented correspond to the mean ± SEM from a representative experiment out of three. (C) Real-time PCR for PU.1 and AID expression in WT, 
1155/155, and miR-155/ B cells. Activation was achieved by stimulating cells with LPS and IL-4 for 4 d. Results are normalized against Hprt or -actin 
expression and relative to the PU.1 and AID WT expression, respectively. Results are from three independent experiments with two to three mice per  
genotype per experiment. (D) Western blotting analysis of PU.1 in WT, PU.1155/155, and miR-155/ LPS-stimulated B cells for 4 d. Duplicate samples are 
shown with tubulin as loading control. Fluorescence intensity relative to WT is also shown. The results shown are representative of two experiments, with 
two mice per group. (E) Ex vivo pre–B cells (B220low, IgM, CD25+) and myeloid cells (Gr-1+/Mac-1+) from WT, PU.1155/155, and miR-155/ mice isolated 
from bone marrow by FACS sorting. PU.1 expression was measured by q-PCR using Hprt as control. Data represent the mean ± SEM from four mice per 
group. Statistical significance was assessed using one way ANOVA. *, P < 0.05; **, P < 0.001; ***, P < 0.0001. NS, not significant.
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Table 1. Normal lymphoid and myeloid development in PU.1155/155 mice
No. of cells Pax-5 (MFI)
WT PU.1155/155 miR-155/ WT PU.1155/155 miR-155/
Marrow
Pre-proa 2 × 105 ± 1 × 105 3.0 × 106 ± 5 × 104 2.6 × 105 ± 8 × 104
Pre Bb 1.8 × 106 ± 1 × 105 2.9 × 106 ± 7 × 105 2.2 × 106 ± 6 × 105 2.2 × 104 ± 3 × 103 2.4 × 104 ± 3 × 103 2.3 × 104 ± 3 × 103
Immature Bc 9 × 105 ± 1 × 105 1.2 × 106 ± 3 × 105 9 × 105 ± 2 × 105 2.8 × 104 ± 4 × 103 3.0 × 104 ± 3 × 103 3.0 × 104 ± 3 × 103
Mature Bd 9 × 105 ± 2 × 105 1.2 × 106 ± 3 × 105 1.1 × 106 ± 1 × 105 1.2 × 104 ± 1 × 103 1.3 × 104 ± 6 × 102 1.3 × 104 ± 1 × 103
Myeloide 2.2 × 107 ± 5 × 106 2.3 × 107 ± 2 × 106 1.9 × 107 ± 3 × 106 2.2 × 104 ± 3 × 103 2.4 × 104 ± 3 × 103 2.3 × 104 ± 3 × 103
Spleen +++
CD4 T 2.9 × 106 ± 6 × 105 2.5 × 106 ± 7 × 105 2.7 × 106 ± 9 × 105
CD8 T 2.2 × 106 ± 9 × 105 2.5 × 106 ± 1 × 105 2.5 × 106 ± 8 × 105
T1 B cellsf 5.1 × 105 ± 2 × 105 4.8 × 105 ± 2 × 105 8.3 × 105 ± 2 × 105 1.7 × 104 ± 2 × 102 1.6 × 104 ± 8 × 102 1.6 × 104 ± 7 × 102
T2 B cellsg 4.9 × 105 ± 2 × 105 5.3 × 105 ± 3 × 105 7.0 × 105 ± 1 × 105 1.7 × 104 ± 3 × 102 1.5 × 104 ± 6 × 102 1.5 × 104 ± 8 × 102
T3 B cellsh 2.7 × 105 ± 9 × 104 2.7 × 105 ± 1 × 105 3.4 × 105 ± 6 × 104 1.4 × 104 ± 1 × 103 1.3 × 104 ± 5 × 102 1.3 × 104 ± 6 × 102
Fo B cellsi 1.6 × 107 ± 5 × 106 1.6 × 107 ± 5 × 106 1.7 × 107 ± 2 × 106 9.5 × 103 ± 2 × 102 8.8 × 104 ± 4 × 102 8.6 × 103 ± 4 × 102
MZ B cellsj 8.7 × 105 ± 2 × 105 7.4 × 105 ± 2 × 105 1.4 × 106 ± 3 × 105 1.4 × 104 ± 2 × 102 1.2 × 104 ± 6 × 102 1.2 × 104 ± 7 × 102
Myeloid cellsk 4 × 106 ± 1 × 106 4 × 106 ± 1 × 106 5 × 106 ± 1 × 106
Peritoneal  
cavity
B1al B1a i 1.3 × 105 ± 5 × 104 2 × 105 ± 1 × 105 9.0 × 103 ± 9 × 102 8.4 × 103 ± 6 × 102 7.5 × 103 ± 7 × 102
B1bm B1b ii 7 × 104 ± 3 × 104 9 × 104 ± 5 × 104 8.2 × 103 ± 4 × 102 8.1 × 103 ± 5 × 102 7.5 × 103 ± 5 × 102
B2n B2 iii 1.6 × 105 ± 7 × 104 5 × 105 ± 3 × 105 8.4 × 103 ± 8 × 102 8.5 × 103 ± 7 × 102 7.7 × 103 ± 8 × 102
Myeloido Myeloid iv 7 × 105 ± 4 × 105 1.2 × 106 ± 8 × 105
Data corresponds to mean and standard deviation from five mice each genotype. Data analysis in is based on one experiment with 4-5 biological 
replicates per genotype.
aB220+/low, IgM- cKit+ iB220high,CD93-, CD23+, IgM+




fB220low,CD93+, CD23low, IgMhigh nCD43low,Mac-1-,B220low
gB220low,CD93+, CD23high, IgMhigh oGr-1+/Mac-1+
hB220low,CD93+, CD23high, IgMlow.
the numbers of cells in the different B cell compartments 
(B1, B2, and marginal zone B cells) are not affected by changes 
in PU.1 abundance (Table 1), this result strongly suggests 
an activation defect. Therefore, we next measured the antigen-
specific IgM and IgG1 responses to the immunogen NP-KLH 
in alum over time. At an early time point, day 7, we observed 
a decrease on antigen-specific antibody secretion in the 
PU.1155/155 mice, although less severe than in the miR-155/ 
mice, which was absent at later time points (Fig. 2 B and not 
depicted). These results suggest that miR-155 regulation of 
PU.1 is required for an optimal extrafollicular response but 
does not affect the GC output, suggesting the involvement of 
additional miR-155 targets in the context of the GC response. 
The early extrafollicular response is dominated by antibody 
production that is dependent on the rapid differentiation 
of proliferating B cells into IgM or IgG1 ASC located in 
secondary lymphoid organs (Jacob et al., 1991b). Quantita-
tion of the number of NP-specific IgM or IgG1 ASCs in the 
spleen by ELISPOT at day 7 allows direct examination of the 
extrafollicular response. The number of NP-specific IgM ASC 
in PU.1155/155 mice was reduced relative to WT mice to 
an extent similar to that in miR-155/ mice (Fig. 2 C). 
However, NP-specific IgG1 ASC from PU.1155–/155– mice, al-
though significantly reduced relative to WT, were not as severely 
impaired as in the miR-155/ response (Fig. 2 C). We wished 
to determine whether the impaired antibody production 
in PU.1155/155 mice was intrinsic to B cells. To this end, 
we created mixed chimeras by transferring 20% of WT, 
PPU.1155/155, or miR-155–deficient bone marrow cells 
with 80% of MT-mutated bone marrow cells into suble-
thally irradiated MT mice, as previously described (Vigorito 
et al., 2007). The MT mutation prevents the generation of 
B cells, so the B cells in the chimeras will be WT, PU.1155/155, 
or miR-155 deficient. The 20/80 ratio favors reconstitution 
of all the other hemopoietic lineages from WT precursors. The 
three groups of chimeras had similar proportions and num-
bers of B, CD4+, and CD8+ T cells (unpublished data). 
Analysis of the extrafollicular response in the PU.1155/155 
and miR-155–deficient chimeras recapitulated the pheno-
type observed in the corresponding germline mice: specifi-
cally, reduced number of NP-specific IgM and IgG1 ASC in 
the spleen 7 d after immunization (Fig. 2 D). These results 
demonstrate a B cell–intrinsic requirement for down-regulation 
of PU.1 by miR-155 at the early stages of a T cell–dependent 
response. In summary, our results not only demonstrate that 
PU.1 is a functional target of miR-155 that regulates the output 
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Impaired plasma cell differentiation  
in activated PU.1155/155 B cells correlates  
with increased expression of Pax5
To assess CSR and plasma cell differentiation independently 
of cell proliferation (Hasbold et al., 2004), we labeled B cells 
of the extrafollicular response but also uncover a novel inhibi-
tory role of PU.1 in terminal B cell differentiation in vivo. Our 
results also suggest that the amount of PU.1 is under stringent 
control in vivo, and small changes in its expression, due to 
miRNA regulation, affect adaptive immune responses.
Figure 2. PU.1 is a negative regulator of Ig secretion in vivo. (A) Steady-state levels of serum IgM (left) and IgG1 (right) analyzed by ELISA. Each 
data point indicates IgM (left) or IgG1 (right) serum concentration (g/ml) from one mouse. Horizontal bars correspond to the mean and the error bars to 
the SEM for the indicated genotype. The experiment was performed twice. (B) Titers of anti–NP-IgM and anti–NP-IgG1 were measured at 7 (left) or 42 d 
(right) after immunization with NP-KLH in alum. Data are present for 5–10 mice from 2 independent experiments. In all cases, each symbol represents 
one mouse. (C) ELISPOT analysis of splenic NP-specific IgM- (left) or IgG1-secreting cells (right) at day 7 after immunization with NP-KLH in alum. Data 
points indicate NP-specific cells per million cells and are presented as mean ± SEM from three different experiments, with three to five mice per genotype per 
experiment. (D) Similar to C, except that the experiment was performed with MT/WT, MT/PU.1155/155, and MT/miR-155/ chimeras. In this experiment,  
5 chimeric mice per group were used. Statistical analysis was assessed with two-sided ANOVA test. *, P < 0.05; **, P < 0.001; ***, P < 0.0001. NS, not significant.
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Figure 3. miR-155 down-regulation of PU.1 controls terminal B cell differentiation. (A) Typical FACS analysis profiles of splenic B220+ cells 
gated for either IgG1 or CD138 plasma cells after culture with LPS and IL-4 for 3 d. These are representative examples from three experiments, each with 
three mice per genotype. (B) Kinetics of LPS/IL-4 activation of WT, PU.1155/155, and miR-155/ B cells. Values presented are percentages of IgG1+ or 
CD138+ cells within the B220+ population. Results are presented as mean ± SD from three experiments with at least three mice of each genotype per 
experiment. (C) Splenic B cells of the indicated genotypes were CFSE labeled, followed by stimulation with LPS and IL-4. At the indicated time points, pro-
liferation was assessed based on CFSE dilution using FlowJo. The graphs show the percentage of B cells in each generation. Symbols correspond to the 
mean and SEM for three mice, and it is a representative example from three experiments, each with three mice per genotype. Statistical analysis was  
assessed with one-way ANOVA test. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
with 5-(6) CFSE and examined cell surface expression of 
IgG1 and CD138 (a marker of plasmablasts and plasma cells) 
by flow cytometry over a time course of 5 d after stimulation 
with LPS and IL4. Cell division in PU.1155/155 B cells was 
not different from that in WT B cells (Fig. 3, A and C). It was 
also not grossly affected in miR-155/ B cells, as shown here 
(Fig. 3, A and C) and in previous studies (Thai et al., 2007; 
Dorsett et al., 2008; Teng et al., 2008). In contrast, CSR and 
plasma cell differentiation were significantly reduced both 
in PU.1155/155 and miR-155–deficient B cells at all time 
points examined (Fig. 3 B). These observations suggest a de-
velopmental defect independent of cell cycle. Consistent with 
this, we previously showed intact post-switch circle transcrip-
tion in miR-155/ B cells compared with WT (Vigorito et al., 
2007). Disruption of the miR-155–binding site in Aicda  
results in enhanced class switching by B cells (Dorsett et al., 
2008; Teng et al., 2008), indicating that other miR-155 
targets, unlike PU.1, are enhancers of class switching. Our re-
sults establish PU.1 as a consequential target of miR-155 that 
inhibits CSR and plasma cell differentiation.
Conditional deletion of Blimp1 in B cells has revealed 
that the plasma cell differentiation program is initiated by 
down-regulation of Pax5, which is followed by up-regulation 
of Blimp1 (Kallies et al., 2007), although it is still unclear how 
down-regulation of Pax5 is achieved. Expression of Pax5 in 
B cells is dependent on a promoter region regulated by EBF1 
and a potent enhancer in its intron 5 (Decker et al., 2009). 
Interestingly, in early B cell development, the activity of this 
enhancer is regulated by the transcription factors PU.1, IRF4, 
IRF8, and NF-B (Decker et al., 2009). We therefore hypoth-
esized that the inhibitory effect of PU.1 on plasma cell differ-
entiation is caused by a failure of PU.1155/155 B cells 
to down-regulate Pax5. We first tested whether PU.1 binding 
to the Pax5 enhancer is detectable in activated B cells 
and whether that binding is affected by PU.1 abundance. 
To this end, we performed PU.1 chromatin immunoprecipi-
tation (ChIP) followed by q-PCR to amplify the Pax5 en-
hancer element. We observed an increase in PU.1 binding in 
PU.1155/155 and miR-155/ B cells relative to WT levels 
(Fig. 4 A). Next, we looked at Pax5 mRNA and protein to 
determine whether PU.1 abundance, dependent on miR-155 
regulation, may be having an impact on Pax5 expression. 
We sorted undifferentiated day 4 cultured B cells on the basis 
of being B220+, IgG1, and CD138, and then measured 
their expression of Pax5. Our results show that both Pax5 
mRNA and protein levels were increased in PU.1155/155 
and miR-155/ B cells relative to WT (Fig. 4 B and not 
depicted), suggesting that this increase precedes plasma cell 
differentiation and is not affected by it. Consistent with defec-
tive plasma cell differentiation, the expression of Blimp1 was 
lower in PU.1155/155 and miR-155/ relative to WT levels 
(Fig. 4 B). Kinetic analysis showed that expression of PU.1, 
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of PU.1 in PU.1155/155 and miR-155/ B cells, relative to 
WT, starting at day 1 of in vitro activation, followed by an in-
crease in Pax5 and a decrease in Blimp-1 from day 3 (Fig. 4 B). 
Expression of Pax5 at day 3 suggests a slight delay in its up- 
regulation in PU.1155/155 B cells relative to miR-155/  
(Fig. 4 B). We do not know the basis for this difference but it 
does not impact on Blimp-1 levels, which remain equivalent in 
Pax5, and Blimp-1 is equivalent in naive B cells from WT, 
PU.1155/155, and miR-155/mice. This result is consistent with 
the equivalent levels of Pax5 that we observed in developing 
and mature naive B cell populations (Table 1), further reinforc-
ing the view that miR-155 regulation of PU.1 is specific to 
activated B cells. The earliest change observed was the up-
regulation of miR-155 in WT and PU.1155/155 B cells and 
Figure 4. PU.1 down-regulation by miR-
155 controls Pax5 and Blimp1 expression 
in activated B cells. (A) PU.1 binding to an 
enhancer regulatory element in intron 5 of 
Pax5. WT, PU.1155/155, and miR-155/  
B cells were cultured with LPS and IL-4 for 4 d 
and ChIP was performed using rabbit -PU.1 
antibody or an isotype control antibody. Sub-
sequently, real-time PCR was conducted to 
amplify a region in the enhancer element in 
intron 5 of Pax5 and data were normalized 
against -actin. Data shown are fold change 
relative to WT percentage of input. Numbers 
represent the mean ± SEM from four inde-
pendent experiments. (B) B cells from four 
mice of each genotype were cultured with  
LPS and IL-4 for the indicated times. miR-155 
was measured using U6 as reference and its 
expression was calculated relative to ex vivo 
WT B cells. No expression was detected in 
miR-155/ B cells. PU.1 and Blimp1 were 
measured by q-PCR using Hprt as control, 
whereas Pax5 expression was measured by 
flow cytometry. To facilitate the comparison 
to WT cells, expression at each time point  
is normalized to the WT control. Results are 
from two to three independent experiments, 
each with three to four mice per genotype. 
Statistical analysis was assessed with one-way 
ANOVA test. *, P < 0.05; **, P < 0.001;  
***, P < 0.0001.
2190 The miR-155–PU.1 axis controls B cell function | Lu et al.
overlapped with previously reported peaks in naive B cells 
(Heinz et al., 2010), though the total number of genomic re-
gions with PU.1 binding in activated B cells was lower than in 
naive B cells. Nonetheless, similar to what has been seen in naive 
B cells, PU.1 binding in our activated B cells was mostly de-
tected at intra- or intergenic regions remote from the tran-
scription start site (TSS; unpublished data). Close to the TSS, 
a small percentage of binding events are clustered in ex-
pressed genes (8%) and in the up-regulated genes (7%), with 
little binding in the nonexpressed or down-regulated genes 
(unpublished data). We next examined enriched sequence 
elements to uncover the sequence determinants for PU.1 
binding in activated B cells. The most enriched motifs, based 
on de novo motif analysis, were very similar between the 
promoter-proximal and -distal regions and resembled the 
known PU.1 consensus elements AAAGAGGAAGTG (PU.1), 
GGAAGT (PU.1 core), and GGAAGTGAAACT (PU.1:IRF 
composite; Heinz et al., 2010; unpublished data). In expressed 
genes, 73% of all PU.1-binding sites contain a PU.1 or ETS core 
motif, suggesting that PU.1 binds directly to a large fraction 
of its target sites (Fig. 6 A).
Interestingly, the probability of a gene being associated 
with a PU.1 peak increases sharply between the set of non-
expressed genes and the set of differentially expressed genes 
(DEGs) across the three genotypes. Thus, whereas only 1 in 8 
of the nonexpressed genes was associated with a PU.1 peak, 
the frequency increased to 1 in 5 for the expressed genes and 
even further, to 1 in 3.5, for the DEGs (Fig. 6 B). Moreover, 
the presence of a PU.1/IRF or PU.1 binding motif within 
peaks follows a similar trend: 50% of the peaks associated 
with nonexpressed genes contain the motif, compared with 
73 and 83% of the expressed genes and DEGs, respectively 
(Fig. 6 A and not depicted). However, the frequency of the 
different PU.1 motifs (PU.1, PU.1 core, and PU.1/IRF com-
posite) was similar in expressed genes and DEGs (unpublished 
data). The enrichment in the proportion of genes associated 
with peaks concomitant with the enrichment in the presence 
of a recognized PU.1 binding motif in the set of DEGs, sug-
gests this group of genes is enriched in direct PU.1 targets. 
Of note, the proportion of overlapping peaks in PU.1155/155 
and miR-155/ was 89% in DEGs (Table S1).
We next examined the functional characterization of the 
group of genes differentially regulated in both PU.1155/155 
and miR-155/ genotypes relative to WT B cells that are 
direct targets of PU.1 (119 genes, Table S1). Of these genes, 
83% contained PU.1 binding motifs and, for 90% of them, 
PU.1 occupancy in naive B cells had been reported previ-
ously (Heinz et al., 2010), validating our results. The ex-
pression of Prdm1 and Syndican1 measured by RNA-Seq was 
within the background level for all genotypes, arguing against 
plasma cell differentiation taking place in these cultures 
(unpublished data). To determine the potential functional 
role of these gene expression changes, we looked for gene 
ontology (GO) biological processes significantly enriched in 
the list of DEGs that were also direct targets of PU.1. One of 
the highly ranked categories was “immunoglobulin subtype” 
the two genotypes. We propose that in activated B cells, miR-
155 down-regulates Pax5 by inhibiting PU.1 expression.
The plasma cell differentiation defect  
in PU.1155/155-activated B cells can be rescued  
via forced reduction of Pax5 expression
To further elucidate the functional relationship between miR-
155, PU.1, and Pax5, we tested whether reduction of Pax5 in 
PU.1155/155 and miR-155/ B cells would restore plasma 
cell differentiation without affecting WT B cells. To this end, 
we retrovirally transduced 24 h [LPS+IL-4]-activated B-blasts 
with a Pax5 silencing construct, and examined plasma cell and 
CSR 96 h later. Infected cells were monitored by expression of 
GFP from an IRES. Analysis of GFP+ cells from control (empty 
vector)-transduced cells reproduced the plasma cell differen-
tiation defect already described. However, silencing Pax5 
specifically in PU.1155/155 and miR-155/ B cells reverted 
the phenotype, whereas it did not affect WT B cells (Fig. 5, 
A and B). The reversion was restricted to the GFP+ fraction, 
consistent with a specific effect on Pax5 expression (Fig. 5, 
A and B). Moreover, CSR was unaffected by Pax5 silencing in 
all genotypes analyzed (unpublished data). Importantly, the ex-
tent of Pax5 reduction was similar in the three genotypes ana-
lyzed (Fig. 5 C). Collectively, our results suggest that regulation 
of Pax5 by the miR-155–PU.1 axis is an important step in 
B cells optimally differentiating toward plasma cells.
PU.1 target genes are enriched in genes  
encoding Ig superfamily proteins that regulate  
humoral responses in activated B cells
Having established that terminal B cell differentiation is sensi-
tive to changes in PU.1 expression imparted by miR-155, we 
next assessed the impact of PU.1 on the gene expression pro-
gram of activated B cells. After showing that plasma cell dif-
ferentiation is sensitive to PU.1 levels, as an effect of elevated 
Pax5 expression, we turned our attention to CSR. To this end, 
we used culture conditions including LPS and a high concen-
tration of IL-4, with the goal of identifying direct PU.1 tar-
gets important for this process. To identify direct target genes 
that respond to physiological changes in PU.1 concentration 
in activated B cells, we conducted chromatin immuno-
precipitation coupled to deep sequencing (ChIP-Seq) from WT, 
PU.1155/155, and miR-155/-activated B cells. These 
results were combined with RNA deep sequencing (RNA-
Seq) from the same samples. We predicted that genes that are 
differentially expressed in both PU.1155/155 and miR-155/ 
relative to WT might explain the CSR phenotype.
Our ChIP-Seq analysis identified 7,276 PU.1-bound 
genomic regions across the three genotypes. We next sought 
to identify genes expressed in B cells that were targeted by 
PU.1. To this end, we assigned peaks to annotated gene loci 
if peaks were within the gene body or up to ±50 kb beyond 
the gene. We defined as “expressed” genes whose expression 
is on average ≥1 RPKM (reads per kilobase per million 
mapped reads) in at least one of the three genotypes. We found 
that 72% of the PU.1 peaks we assigned to expressed genes 
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protein–protein interactions, critical processes in the context 
of T cell–dependent responses. Genes whose products are 
known to be important for sustaining interactions with T cells 
include Icosl, Pvrl1, Pd1d1l2, and Slamf1, although intrinsic 
roles in B cells for some of them remain to be assessed. Sema-
phorins (Sema 7a, Sema 4a, and Cd300lf), the semaphorin 
ligand Plexin-d1(Plxnd1), and Fc-receptor genes (FcgRIIb, 
 FcgRIV, and Fcrl5) are affected by PU.1 abundance. Proteins en-
coded by another group within the PU.1 targets are important 
in signal transduction downstream of some of the afore-
mentioned receptors or the B cell receptor (Dap12, Rasgrp3, 
Gab2, and Card11). We also found that Ccr7 and Cxcr4, which 
have known roles in the migration of activated B cells, are 
regulated by PU.1. Furthermore, most of the genes we identified 
(P < 1.6 × 105; unpublished data). Moreover, using inge-
nuity pathways analysis, which combines gene ontology 
categories and curated literature, one of the top processes was 
“humoral immune responses: production of antibodies” 
(P < 6.8 × 109; Fig. 6 C). This analysis led to the identifica-
tion of 30 PU.1 target genes with known links to humoral 
immune responses (Fig. 6 C and Table S1). The associated 
PU.1 binding and mRNA expression for some of the targets 
are shown in Fig. 6 (D and E). Similar patterns of expression 
were observed by RNA-Seq and quantitative PCR for 8 out 
of 9 validated genes (Fig. 6 E and not depicted).
Notably, 50% of these genes (Fig. 6 C, in red) encode 
members of the Ig superfamily of polypeptides, suggesting 
that PU.1 regulates genes involved in cellular adhesion and 
Figure 5. Forced reduction of Pax5 expression rescues the 
plasma cell differentiation defect in PU.1155/155 and miR-
155/–activated B cells. (A) Representative plots of the 
CD138 and B220 expression levels in the WT, PU.1155/155, and 
miR-155/ activated B cells after transduction with GFP con-
taining Si-Pax5 or empty control (EV) vector retroviruses. Cells 
were activated for 24 h before addition of the retroviruses, and 
were then cultured in activation media for an additional 3 d. The 
GFP+ populations were selected for analysis. The numbers inside 
the gating boxes show the average percentage of gated popula-
tion from a representative experiment out of three. (B) The bar 
graphs indicate the percentages of CD138-expressing cells 
among GFP+ or GFP gated populations. Data are aggregated 
from three independent experiments with three to four mice per 
group. (C) The Si-Pax5– or EV-transduced cells were sorted and 
gene silencing efficiencies in the WT, PU.1155/155, and miR-
155/ samples were evaluated by qPCR. Bar graphs represent 
the mean from four independent experiments on either GFP+ or 
GFP populations. Statistical analysis was assessed with one-
way ANOVA test. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
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Figure 6. PU.1 targets in activated B cells include genes involved in adhesion and B/T cellular interactions. (A) A large proportion of DEGs bind 
PU.1 through its canonical site. The PU.1 motif was discovered using MEME (The MEME Suite), by alignment of the center (core 200 bp) of the PU.1 ChIP-
peaks in either DEGs (right) or expressed genes minus DEG (left). Percentage of alignment is shown in each category. (B) The frequency of genes associ-
ated with PU.1 binding. The highest percentage of genes with PU.1 peaks was in the DEG category, across WT, PU.1155/155, and miR-155/ B cells, at 
28%. This compares with a percentage of 21% in genes with no change in expression and 12% in genes that are not expressed. The percentage of genes 
with PU.1 peaks relative to the total genes in each category was calculated and presented. P < 0.001, Chi2 test. (C) A group of PU.1-regulated genes with 
links to humoral immune responses. The groups of genes with different known functions were discovered by IPA Ingenuity analysis using the genes that 
were differentially regulated and containing a PU.1-binding peak. Genes that contain Ig domains are colored in red. PU.1 target genes are functionally 
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different but complementary classes. Both groups are enriched 
in adhesion molecules and activation/differentiation mole-
cules. Collectively these results indicate that a large compo-
nent of the transcriptome changes seen in miR-155/  
B cells relative to WT are mediated through a single target, 
namely PU.1.
DISCUSSION
It is well accepted that miRNAs have had a profound impact 
on the evolution of 3 UTRs and that a single miRNA can 
regulate the expression of hundreds of genes, although the 
level of repression imparted to a given target is generally low 
(Stark et al., 2005; Bartel, 2009). What is less evident is how 
the selective pressure for a single miRNA–target interaction 
is maintained across long evolutionary distances when the di-
rect effect of disrupting such an interaction is apparently neg-
ligible. Here, we have shown that the miR-155/PU.1 
interaction, which regulates PU.1 abundance only modestly, is 
key to promoting an optimal T cell–dependent extrafollicular 
B cell response—a previously unrecognized role for PU.1. In 
terms of mechanism, we have shown that, in activated B cells, 
PU.1 sustains Pax5 expression, acting as a negative regulator 
of terminal B cell differentiation. In addition to Pax5, targets 
of PU.1 in activated B cells include proteins involved in ad-
hesion and cellular interactions, with direct links to B–T cell 
interactions. The identification of these genes provides impor-
tant insights into the function of PU.1 in activated B cells.
It has been proposed that some miRNA target genes may 
act as bona fide targets in a particular cell type or cellular 
context but as miRNA-sequestering targets in other circum-
stances (Seitz, 2009). These alternate functions of a particular 
target are probably dictated by the relative abundances of the 
mRNA and miRNA. In this regard, it has recently been 
shown that a given target mRNA displays an expression thresh-
old below which it is repressed by a miRNA but above which 
it titrates out the miRNA with minimal effect on protein 
levels (Mukherji et al., 2011). The down-regulation of PU.1 
in activated B cells concomitant with the up-regulation of 
miR-155 provides a window of effective miRNA/target re-
pression. This effect was very clearly observed in cultured 
B cells and in the context of the extrafollicular response in vivo. 
We propose that conserved miR–target interactions confer 
effectiveness to particular biological processes in a specific time 
window, and that in those circumstances disruption of such 
interactions will have measurable effects.
Our study also shows that a single target can shape signifi-
cantly the overall expression program directed by a miRNA, even 
as transcriptionally regulated by PU.1 are also expressed in 
macrophages and/or dendritic cells, which is consistent with 
the known functions of PU.1 in regulating the transcriptome 
of myeloid cells. Some of the genes we identified have pre-
viously been reported as PU.1 direct targets (Cd80, Flt3, 
FcgrIIb, FcgrIV, Il1r1, Dap12, and Lmo2). Overall, our analysis 
points toward PU.1 regulating the expression of a significant 
number of adhesion molecules, some of which have defined 
roles in cellular interactions required for productive T cell–
dependent responses.
The PU.1–miR-155 interaction alone explains  
a large fraction of the miR-155–induced gene  
expression changes in activated B cells
A Venn diagram showing the distribution of the DEGs in 
PU.1155/155 and miR-155/ relative to WT allows visual 
inspection of the gene expression similarities (Fig. 7 A). In the 
PU.1155/155 B cells, we found 217 up-regulated genes and 
46 down-regulated genes relative to WT levels, indicating that 
miRNA regulation of this single target shapes the transcrip-
tional program of B cells. Of those genes, 62% (134) of those 
up-regulated and 87% (40) of those down-regulated were 
shared with miR-155/ B cells (Fig. 7 A). This number of 
genes is a significant component of the differentially regu-
lated genes in miR-155/ B cells, as they represent 50% of 
the up-regulated and 33% of the down-regulated genes. The 
strong overlap of the transcriptomes of PU.1155/155 and 
miR-155/ B cells suggests that PU.1 plays an important 
role in the gene expression changes imparted by miR-155. As 
reported before, a large fraction of the genes up-regulated in 
miR-155/ B cells is enriched with miR-155 responding 
elements in their 3UTRs, but the same is not observed in the 
down-regulated genes (Fig. 7 B; Rodriguez et al., 2007). The 
genes exhibiting enrichment of miR-155–binding motifs are 
dominated by the group of genes up-regulated in miR-155 
only (Fig. 7, B and C), in line with previous studies showing 
that miR-155 in B cells directly regulates tens of genes in 
addition to PU.1 (Vigorito et al., 2007; Fabani et al., 2010). 
Interestingly, the fold-change in expression of DEGs relative 
to WT levels was generally higher in miR-155/ than in 
PU.1155/155 B cells (Table S1 and not depicted), despite the 
two types expressing similar levels of PU.1. This suggests that 
(some of ) the additional miR-155 targets may act coopera-
tively with PU.1. When we sorted DEGs, which are PU.1 
targets into those with (i) similar expression in miR-1555/ 
and PU.1155/155 or (ii) higher expression in miR-155/ 
versus PU.1155/155, GO analysis showed enrichment in 
enriched in those that encode adhesion molecules that regulate Ig secretion. Ingenuity Pathway Analysis (right) was performed using genes that were 
differentially expressed and contain PU.1 binding peak(s). A summary of the most statistically significant pathways with their P values is shown. (D) Seq-
monk browser tracks of PU.1 binding at the locus of some of the genes reported to have a role in humoral immunity. WT, PU.1155/155, and miR-155/ 
B cell samples are represented, with input shown as background. Green boxes highlight the binding peak/s observed. (E) The mRNA expression of PU.1 
target genes with reported roles in humoral immunity. Expression values are normalized RPKM, determined from 4 to 5 biological replicates in each of the 
genotypes or AU for q-PCR measured from 3 experiments with 3–4 mice per group. Statistical analysis was assessed with one-way ANOVA test. *, P < 0.05;  
**, P < 0.001; ***, P < 0.0001. Data analysis in A–D is based on one experiment with 4–5 biological replicates per genotype.
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may be occurring. It is likely that an answer to this will emerge 
from the analysis of in vivo activated B cells from PU.1155/155 
and miR-155/ mice and this is an area that requires fur-
ther investigation.
It is well recognized that effective transitions through de-
velopmental programs require strict control of the abundance 
of regulatory components. Posttranscriptional control of gene 
expression by miRNAs provides an effective mechanism to 
ensure timely transitions across developmental stages. In fact, 
dose-sensitive genes that regulate B cell activation in vivo, 
such as Irf4, Bcl6, Aicda, or Prdm1, are susceptible to miRNA 
regulation (de Yébenes et al., 2008; Teng et al., 2008; Malumbres 
though the miRNA has many additional targets, as indicated 
by the extensive overlap in the transcriptomes of PU.1155/155 
and miR-155/-activated B cells. Despite the strong impact 
of PU.1 on miR-155 regulation of gene expression, we con-
sistently observed that the fold-change in expression of DEGs 
relative to WT levels was higher in miR-155/ than in 
PU.1155/155 B cells. In other words, most of the DEGs in 
PU.1155/155 B cells show intermediate expression relative to 
WT and miR-155/. This is also manifested in the impaired 
Ig production in vivo, which is more severe in the miR-155/ 
mice. At present we do not know the basis of this phenome-
non but suggest that synergy with additional miR-155 targets 
Figure 7. PU.1 explains a large fraction 
of changes in the transcriptome of miR-
155–deficient B cells. (A) Venn diagrams 
intersecting the number of genes up-regulated 
or down-regulated in PU.1155/155, or miR-
155/ samples, compared with WT. All genes 
tested are from the DEG group of genes listed 
in Table S1. (B) Sylamer analysis for genes 
either up- or down-regulated in miR-155/ 
compared with WT, for enrichment of miR-
155–binding sites (6-mer, 7-mer, or 8-mer 
composition). Also tested were genes up-
regulated in miR-155/ but down-regulated 
or without change in expression in 
PU.1155/155 samples. Significance was calcu-
lated by comparing enrichment of the  
miR-155 seed sequence in these selected 
groups of genes to all the genes containing a 
3UTR in the mouse genome. (C) Venn dia-
gram intersecting the number of genes with 
miR-155–binding sites in PU.1155/155 or 
miR-155/ up-regulated genes. Percentages 
in brackets represent the number of genes 
with miR-155–binding sites as a proportion 
of the total number of up-regulated genes.
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regulates T cell function via binding of its ligand CD6 that 
appears to have inhibitory signaling function (Oliveira et al., 
2012), whereas CD80 preferentially recruits the inhibitory 
molecule CTLA-4 to the T cell immunological synapse and 
may as a consequence inhibit T cell activation (Pentcheva-
Hoang et al., 2004). Additional PU.1 targets include Sirpa and 
Adora, both of which regulate T cell activation and effector 
function; however, their roles in B cells have yet to be studied. 
Overall, our results establish a novel negative regulatory func-
tion for PU.1 in activated B cells and identify a wide set 
of targets. In addition to Pax5 we have uncovered a set of 
genes with roles in cell adhesion and cellular communica-
tion that may regulate B–T cell interaction to mediate effec-
tive immune responses. Our study also highlights the need to 
manipulate miRNA–target interactions in physiological set-
tings to advance our understanding on miRNA biology. It is 
only in this way that we can formally establish cause–effect 
relationships and distinguish epistasis between miRNAs and 
their targets.
MATERIALS AND METHODS
Mice. miR-155 mice, described previously (Rodriguez et al., 2007), were 
backcrossed six times to C57BL/6J. C57BL/6J mice were obtained from The 
Jackson Laboratory and were bred at the Babraham Institute. PU.1155/155 
mice were generated at the Babraham Institute (details below). All animal ex-
perimentation complied with UK Home Office regulations and was approved 
by the local ethical review process at The Babraham Research Campus.
Generation of PU.1155/155 mice and chimeras. The PU.1155/155 
targeting construct was derived from a previously described PU.1 knock-out 
targeting vector (Dakic et al., 2005). In brief, a fragment of 1.1-kb flanking 
the miR-155–binding site in the 3UTR of PU.1 was cleaved from the tar-
geting vector using the restriction enzyme SalI. This was cloned into pBlue-
script SK in which site direct mutagenesis was performed using the Quick 
Change Multi Site kit (Agilent Technologies) with the following primers: 
5-GACCCCGCCGGCCATAGATGCATCCCGTCGCCCGGCCCGG-3 
and 5-CCGGGCCGGGCGACGGGATGCATCTATGGCCGGCGGG-
GTC-3. The nucleotides underlined indicate those mutated. The mutation 
introduces an NsiI restriction site, which was used for genotyping purposes. 
Once the mutation had been sequence verified, the mutated fragment was 
cloned back into the targeting vector using the same SalI restriction site and 
checked for correct orientation by restriction profile and sequencing. The 
linear targeting vector was transfected into C57BL/6 ES cells. Neomycin-
resistant clones were screened by Southern hybridization and chimeras de-
rived from blastocyst injection of these targeted clones were crossed to obtain 
germline transmission. FLPe mice were then crossed with the PU.1155/GFP 
mice for the removal of the IRES-GFP-Neomycin cassette and to obtain 
PU.1155/+ mice. Further breeding produced the PU.1155/155 homozygous 
mice used in this study. For the generation of mixed chimeras, 500-rads irra-
diated MT mice received 5 × 106 of a mixture of 80% bone marrow cells 
of MT origin and 20% WT, PU.1155/155, or miR-155–deficient bone 
marrow cells. Reconstitution was assessed 6 wk later by measuring B and 
T cells from blood.
Luciferase assay. The Sfpi1 3UTR was amplified from genomic DNA and 
inserted into the psiCheck-2 Renilla luciferase reporter plasmid (Promega, 
(Vigorito et al., 2007)). This construct was used to derive a miR-155 “seed” 
mutant plasmid with the Quik Change Multi Site Mutagenesis kit (Agilent 
Technologies). The mutagenic primers used were the same reported in the 
previous section to generate the knock-in mice. The correctness of all 
plasmids was confirmed by sequencing. Reporter assays were performed in 
et al., 2009; West et al., 2009; Gururajan et al., 2010; Borchert 
et al., 2011; Chaudhuri et al., 2011; Lin et al., 2011; Huang 
et al., 2012). Although the significance of some of the aforemen-
tioned posttranscriptional regulation events remains to be ex-
plored in vivo, the interplay between transcription factors and 
miRNAs is emerging as a common theme in gene regulatory 
networks (Le et al., 2013). We show here that regulation of 
PU.1 abundance by miR-155 in activated B cells impacts on 
terminal B cell differentiation in vivo and in vitro. The in-
creased expression of PU.1, due to lack of miR-155 regu-
lation, results in higher levels of Pax5 and lower levels of 
Blimp-1 concomitant with a reduction of plasma cells. More-
over, we were able to restore plasma cell differentiation in 
miR-155/ and PU.1155/155 B cells by simply reducing 
Pax5 expression. In agreement with our results, sustained 
ectopic expression of Pax5 in murine splenocytes activated 
with LPS has been shown to inhibit plasma cell formation (Lin 
et al., 2002). In agreement with our results, Carotta et al. (this 
issue) have observed that overexpression or reduction of 
PU.1 expression in mature B cells affected Pax-5 and Blimp1 
expression, suggesting a role for PU.1 as a negative regulator 
of plasma cell differentiation. Therefore, we propose that 
miR-155 regulates the initiation of the plasma cell differenti-
ation pathway through the inhibition of PU.1, which in turn 
regulates the expression of Pax5.
Genome-wide characterization of genes regulated tran-
scriptionally by PU.1 shows that several of them encode mem-
brane receptors with roles in cellular adhesion and intercellular 
communication. This functional pattern is consistent with 
previous reports mainly focused on myeloid cells (Turkistany 
and DeKoter, 2011), suggesting a broader role for PU.1 in 
the regulation of antigen-presenting function in myeloid and 
B cells. Among the genes regulated by PU.1 are Plexin-d1, 
semaphorin family members, and Dap12, which can act as an 
adaptor for Plexin-d1. Plexin-d1 plays a B cell–intrinsic role 
in T cell–dependent responses, probably by regulating B cell 
migration within germinal centers (Yu et al., 2008; Holl et al., 
2011). In addition to the already characterized PU.1 target 
FcgRIIb, Fcgr3a and Fcrl5 also appear to be direct targets of 
PU.1. Although there is still controversy over the identity of 
the ligand for Fcrl5, it is clear it can provide inhibitory signals 
to human B cells (Haga et al., 2007), which may contribute to 
explaining the inhibitory role of PU.1 in activated B cells. 
A group of target genes (IcosL, PD1lg2, Pvrl1 [Nectin-1], 
and Slamf1) with well-defined roles in T follicular helper cell 
interactions has been identified. With the exception of the 
negative regulator PD1lg2, these genes appear to be activated 
transcriptionally by PU.1, and hence promote stronger inter-
actions with T follicular helper cells: the possibility that col-
lective changes in the expression of these genes could impact 
on intercellular communication in activated B cells remains 
to be tested. A theme on the regulation of T cell interactions 
is also suggested by PU.1 regulating Alcam and CD80, the 
latter already described as a target of PU.1 (Bowen et al., 1995; 
Kanada et al., 2011). Both Alcam and CD80 are known to be 
expressed by activated B cells (Bowen et al., 1995). Alcam 
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RNAi gene silencing assay. The target sequence was introduced into the 
pMig empty retroviral vector via the BLOCK-iT polII miR RNAi vector 
kit (Invitrogen). The vectors were sequence confirmed before being intro-
duced into the Plat-E retroviral packaging system with the X-treme GENE 
HP DNA transfection reagent (Roche). Retroviral supernatants were treated 
with PEG-iT virus precipitation solution (System Biosciences) for 12 h 
before centrifuged for 30 min at 500 g. All retroviral vectors expressed GFP, and 
an empty retroviral vector containing GFP only was used as the control.
Chromatin immunoprecipitation. Cultured B cells stimulated for 4 d 
with LPS (5 µg/ml) and IL-4 (10 ng/ml) were treated with 2% formaldehyde 
to cross-link the DNA and protein and incubated for 5 min at room temper-
ature. This reaction was quenched by adding glycine to a final concentration 
of 125 mM. Cells were then permeabilized in 5 mM PIPES, pH 8.0, 85 mM 
KCl, 0.5% NP-40, and protease inhibitor cocktail (Roche) for 15 min at 4°C. 
Lysis buffer consisting of 1% SDS, 10 mM EDTA, and 50 mM Tris-HCl was 
applied to the permeabilized cells before fragmentation using a Diagenode 
Bioraptor UCD-200 sonicator.
Fragmented chromatin was diluted to 50 µg/ml in ChIP buffer, contain-
ing 0.01% SDS, 1.1% Triton-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, 167 mM 
NaCl, and protease inhibitors cocktail (Roche). 1 ml was used per immuno-
precipitation reaction and 100 µl was used as input control. The chromatin 
was incubated with either 2.0 µg of rabbit -PU.1 (T-21 clone; Santa Cruz 
Biotechnology, Inc.) or the same amount of IgG isotype control overnight 
and precipitated using 50 µl protein A-coated magnetic beads (Invitrogen). Pre-
cipitates were then reverse cross-linked, mRNA and proteins were digested 
using RNase A and proteinase K by incubating at 37 °C for 1 h and at 65°C 
overnight. After phenol/chloroform extraction, DNA was precipitated using 
isopropanol and resuspended in TE.
Library preparation for ChIP-Seq and RNA-Seq. ChIP-Seq libraries 
were constructed essentially following Illumina’s standard ChIP-Seq library 
construction protocols. RNA-Seq libraries were constructed using the Tru-
Seq sample preparation kit (Illumina) except that after the first strand synthe-
sis, the reaction mixture was cleaned up using the QIAQuick purification 
columns (QIAGEN) and the second strand synthesis was made using dUTP 
instead of dTTP. Just before the PCR amplification step, UNG (Ambion) was 
used to digest the second (opposite) strand containing uracil, to make it 
strand-specific. Both ChIP and RNA libraries were run on the Bioanalyzer 
for quality control to check purity and size range.
Sequencing and read alignment. ChIP-Seq was performed on the Illu-
mina Genome Analyser IIx using the 36-bp read length program. RNA-seq 
was performed on the Hi-Seq 2000 using the 75-bp read length program. 
The barcoded samples were then de-multiplexed and mapping was per-
formed with the NCBIM37 (mm9) reference genome using Bowtie for 
ChIP-Seq and TopHat for RNA-Seq, respectively.
Peak calling and motif analysis for ChIP-seq. ChIP-Seq peaks were 
called using the default parameters on the MACS software version 1.3.6.1 
(Zhang et al., 2008) and viewed using the SeqMonk program. For PU.1 
motif discovery, the center 200 bp of called peaks were analyzed using the 
MEME suite program (Bailey et al., 2009) for alignment. For cis-regulatory 
motif analysis, the same sequences used in the MEME program were run in 
the RSAT pattern matching program using predefined motifs (Heinz et al., 
2010). For PU.1 motif discovery, the center 200 bp of called peaks were an-
alyzed using the MEME suite program (Bailey et al., 2009) for alignment.
Transcriptome annotation and quantification. To determine whether 
a given gene is defined as “expressed,” an initial quantitation was made by 
counting the number of RPKM, where the normal distribution was viewed 
and an expression cut-off of RPKM=1 was chosen. To identify significantly 
changing genes, RPM values were quantitated. Differential expression was 
called by selecting transcripts, which changed with a significance of P < 0.05 
after Benjamini and Hochberg correction using a null model constructed 
HeLa cells co-transfected in triplicates using Lipofectamine 2000 (Invitro-
gen) with test plasmid (3UTR PU.1 WT or mutant) along with the indi-
cated mimic at a final concentration of 40 nM. Firefly luciferase was used as 
a normalization control. Reporter activity was detected 24 h after transfec-
tion with the Dual-Glo Luciferase Assay System (Promega). Expression val-
ues were normalized against the average value for the corresponding plasmid 
as in (Rodriguez et al., 2007).
Immunization, ELISA, and ELISPOT. To elicit a T cell–dependent im-
mune response, 100 µg of alum-precipitated NP-KLH (Biosearch Tech) was 
used. NP-specific antibodies were detected by ELISA, as previously described 
(Vigorito et al., 2007), except that antibody end point titers were used as a 
measurement of relative concentration. NP-specific AFCs were detected 
with ELISPOT as previously described (Xiang et al., 2007). In brief, 96-well 
plates (Millipore) were coated with NP23-BSA and blocked with 10% FCS 
in medium before the addition of splenic cells. Cells were incubated over-
night under 5% CO2 at 37°C in complete medium (see Cell culture and 
FACS analysis). Cells secreting anti-NP antibody were visualized with HRP 
anti–mouse IgM or IgG1 followed by ACE staining (Sigma-Aldrich).
RNA extraction and qPCR. Total RNA was extracted using TRIzol 
(Invitrogen) according to the manufacturer’s protocol. cDNA synthesis was 
performed using Superscript III (Invitrogen). qPCR analysis was performed 
using the SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich). A list of 
the primers used is shown in Table S2. Cycling conditions were as follows: 
Step 1, 2 min at 95°C; Step 2, 15 s at 95°C; Step 3, 30 s at 65°C; Step 4, 30 s 
at 72°C. Steps 2–4 were repeated for 40 cycles. Data acquired were analyzed 
using the software supplied by the manufacture (Bio-Rad Laboratories). 
Relative quantifications of gene expression were calculated using either Hprt 
or -actin as control. miR-155 was quantified using a TaqMan assay and U6 
as control according to manufacturer’s instructions. In the Pax5 ChIP qPCR, 
primers amplifying a region in the enhancer element in intron 5 were applied 
to DNA fragments immunoprecipitated using an anti-PU.1 antibody (Santa 
Cruz Biotechnology, Inc.) and normalized against -actin. In the sorted 
GFP+ retrovirally transfected cells, the QuantiTect SYBR Green RT-PCR 
system was used (QIAGEN).
Western blotting. Western blots were performed on cell lysates prepared 
using 100 µl of RIPA buffer, consisting of 150 mM NaCl, 50 mM Tris-HCl 
pH 8, 1% NP-40, 0.5% deoxycholate, and 0.1% SDS per 107 stimulated sple-
nocytes. Protein concentration was measured using a BCA assay (Thermo 
Fisher Scientific) and 50 µg of protein lysate were loaded per lane onto an 8% 
SDS-PAGE gel. After electrophoresis, the separated polypeptides were trans-
ferred to a nitrocellulose membrane and immunostained using a rabbit anti-
PU.1 antibody (Santa Cruz Biotechnology, Inc.), anti-Pax5 (Holmes et al., 
2006), or mouse anti-tubulin (Sigma-Aldrich) primary antibodies. IRDye 
800 anti–rabbit IgG and Alexa Fluor 680 anti–mouse IgG (Invitrogen) were 
used for development and imaging. Blot images were analyzed on a Li-COR 
Odyssey system.
Cell culture and FACS sorting. Lymphocytes were isolated from the 
spleen of mice by density gradient separation using Lympholyte-M (Cedarlane). 
B cells were further purified using a negative selection B cell isolation kit 
(Miltenyi Biotec). Cells were cultured in RPMI-1640 (Invitrogen) contain-
ing 10% FCS, 2 mM l-glutamine, 2-mercaptoethanol, and 1% penicillin/
streptomycin. To monitor proliferation, up to 107 cells were labeled with 
25 µM CFSE for 10 min to track cell division. Cells were stimulated with 
5 µg/ml LPS (Sigma-Aldrich) and 10 ng/ml of IL-4 (PeproTech). Cells were 
surface-stained with antibodies listed in Table S2 and with DAPI (Invitrogen) 
for exclusion of dead cells. For Pax5 intracellular staining, the cells were fixed 
with the Foxp3 staining buffer set (eBioscience) according to manufacturer’s 
instructions. Data were acquired in a LSRFortessa or LSRII (BD) and ana-
lyzed on FlowJo (Tree Star). All cell sorting was performed on a FACSAria 
III instrument (BD).
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